{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T21:43:47Z","timestamp":1763415827109,"version":"3.45.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-23810-5","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T21:03:28Z","timestamp":1763413408000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tenofovir alafenamide fumarate use for HIV pre-exposure prophylaxis and weight gain"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5603-5398","authenticated-orcid":false,"given":"Fanghui","family":"Shi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiyi","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Weissman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"23810_CR1","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.2019.1343","volume":"321","author":"AS Fauci","year":"2019","unstructured":"Fauci, A. S., Redfield, R. R., Sigounas, G., Weahkee, M. D. & Giroir, B. P. Ending the HIV epidemic: A plan for the United States. Jama 321, 844\u2013845 (2019).","journal-title":"Jama"},{"key":"23810_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jama.2022.22246","volume":"329","author":"RT Gandhi","year":"2023","unstructured":"Gandhi, R. T. et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the international antiviral society\u2013USA panel. Jama 329, 63\u201384 (2023).","journal-title":"Jama"},{"key":"23810_CR3","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1001\/jama.2024.16984","volume":"332","author":"MA Spinelli","year":"2024","unstructured":"Spinelli, M. A., Ngure, K. & Gandhi, M. Preexposure prophylaxis (PrEP) for HIV. JAMA 332, 1574\u20131575 (2024).","journal-title":"JAMA"},{"key":"23810_CR4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1089\/apc.2024.0158","volume":"38","author":"A Oglesby","year":"2024","unstructured":"Oglesby, A. et al. Pre-exposure prophylaxis for the prevention of HIV-1: An assessment of oral pre-exposure prophylaxis usage patterns, first evidence of HIV-1, and HIV-1 risk factors in the United States. AIDS Patient Care STDs. 38, 495\u2013506 (2024).","journal-title":"AIDS Patient Care STDs"},{"key":"23810_CR5","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/jama.2023.9865","volume":"330","author":"R Chou","year":"2023","unstructured":"Chou, R. et al. Preexposure prophylaxis for the prevention of HIV: Updated evidence report and systematic review for the US preventive services task force. JAMA 330, 746\u2013763 (2023).","journal-title":"JAMA"},{"key":"23810_CR6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0140-6736(20)31065-5","volume":"396","author":"KH Mayer","year":"2020","unstructured":"Mayer, K. H. et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): Primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet 396, 239\u2013254 (2020).","journal-title":"Lancet"},{"key":"23810_CR7","doi-asserted-by":"publisher","first-page":"e397","DOI":"10.1016\/S2352-3018(21)00071-0","volume":"8","author":"O Ogbuagu","year":"2021","unstructured":"Ogbuagu, O. et al. Long-term safety and efficacy of emtricitabine and Tenofovir Alafenamide vs emtricitabine and Tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: Week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet HIV. 8, e397\u2013e407 (2021).","journal-title":"Lancet HIV"},{"key":"23810_CR8","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1089\/apc.2023.0158","volume":"37","author":"G Jin","year":"2023","unstructured":"Jin, G. et al. Pre-exposure prophylaxis care continuum for HIV risk populations: An umbrella review of systematic reviews and meta-analyses. AIDS Patient Care STDs. 37, 583\u2013615 (2023).","journal-title":"AIDS Patient Care STDs"},{"key":"23810_CR9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1001\/jama.2023.11700","volume":"330","author":"AY Liu","year":"2023","unstructured":"Liu, A. Y., Scott, H. M. & Buchbinder, S. P. New USPSTF guidelines for HIV preexposure prophylaxis: Will more choices lead to greater impact? Jama 330, 699\u2013701 (2023).","journal-title":"Jama"},{"key":"23810_CR10","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1056\/NEJMsr1809937","volume":"381","author":"The All of Us Research Program Investigators","year":"2019","unstructured":"The All of Us Research Program Investigators. The all of Us research program. N. Engl. J. Med. 381, 668\u2013676 (2019).","journal-title":"N. Engl. J. Med."},{"key":"23810_CR11","doi-asserted-by":"publisher","first-page":"ooad071","DOI":"10.1093\/jamiaopen\/ooad071","volume":"6","author":"X Yang","year":"2023","unstructured":"Yang, X. et al. Computational phenotyping with the all of Us research program: Identifying underrepresented people with HIV or at risk of HIV. JAMIA open. 6, ooad071 (2023).","journal-title":"JAMIA open."},{"key":"23810_CR12","doi-asserted-by":"publisher","unstructured":"Shi, F. et al. Identification of transgender and gender-diverse individuals in the all of Us research program, 2017\u20132022. Am. J. Public. Health, e1\u2013e10 https:\/\/doi.org\/10.2105\/ajph.2025.308129 (2025).","DOI":"10.2105\/ajph.2025.308129"},{"key":"23810_CR13","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40121-020-00384-5","volume":"10","author":"SD Fields","year":"2021","unstructured":"Fields, S. D. & Tung, E. Patient-focused selection of PrEP medication for individuals at risk of HIV: A narrative review. Infect. Dis. Therapy. 10, 165\u2013186 (2021).","journal-title":"Infect. Dis. Therapy"},{"key":"23810_CR14","doi-asserted-by":"publisher","first-page":"ofab542","DOI":"10.1093\/ofid\/ofab542","volume":"8","author":"BR Wood","year":"2021","unstructured":"Wood, B. R. & Huhn, G. D. Excess weight gain with integrase inhibitors and tenofovir alafenamide: What is the mechanism and does it matter? Open. Forum Infect. Dis. 8, ofab542. https:\/\/doi.org\/10.1093\/ofid\/ofab542 (2021).","journal-title":"Open. Forum Infect. Dis."},{"key":"23810_CR15","doi-asserted-by":"publisher","first-page":"e25702","DOI":"10.1002\/jia2.25702","volume":"24","author":"PW Mallon","year":"2021","unstructured":"Mallon, P. W. et al. Weight gain before and after switch from TDF to TAF in a U.S. cohort study. J. Int. AIDS Soc. 24, e25702. https:\/\/doi.org\/10.1002\/jia2.25702 (2021).","journal-title":"J. Int. AIDS Soc."},{"key":"23810_CR16","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1097\/QAD.0000000000002930","volume":"35","author":"K McCann","year":"2021","unstructured":"McCann, K. et al. Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes. Aids 35, 1657\u20131665 (2021).","journal-title":"Aids"},{"key":"23810_CR17","doi-asserted-by":"publisher","first-page":"e2332968","DOI":"10.1001\/jamanetworkopen.2023.32968","volume":"6","author":"AS Rivera","year":"2023","unstructured":"Rivera, A. S., Pak, K. J., Mefford, M. T. & Hechter, R. C. Use of tenofovir alafenamide fumarate for HIV pre-exposure prophylaxis and incidence of hypertension and initiation of Statins. JAMA Netw. Open. 6, e2332968\u2013e2332968 (2023).","journal-title":"JAMA Netw. Open."},{"key":"23810_CR18","doi-asserted-by":"crossref","unstructured":"Shah, S., Pilkington, V. & Hill, A. Is tenofovir disoproxil fumarate associated with weight loss? Aids 35, S189\u2013S195 (2021).","DOI":"10.1097\/QAD.0000000000003083"},{"key":"23810_CR19","first-page":"e25702","volume":"24","author":"PW Mallon","year":"2021","unstructured":"Mallon, P. W. et al. Weight gain before and after switch from TDF to TAF in a US cohort study. Afr. J. Reprod. Gynaecol. Endoscopy. 24, e25702 (2021).","journal-title":"Afr. J. Reprod. Gynaecol. Endoscopy"},{"key":"23810_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.36469\/jheor.2022.31825","volume":"9","author":"B Emond","year":"2022","unstructured":"Emond, B. et al. Real-world analysis of weight gain and body mass index increase among patients with HIV-1 using antiretroviral regimen containing Tenofovir alafenamide, Tenofovir disoproxil fumarate, or neither in the United States. J. Health Econ. Outcomes Res. 9, 39 (2022).","journal-title":"J. Health Econ. Outcomes Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23810-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23810-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23810-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T21:03:29Z","timestamp":1763413409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23810-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["23810"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-23810-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"9 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Only the authorized authors who completed AoU Responsible Conduct of Research training accessed the data from the Researcher Workbench. All research using data made available via the AoU Researcher Workbench has been designated as non-human subjects by the AoU Institutional Review Board. Since the authors were not directly involved with the participants and Researcher Workbench employs a data passport model, IRB review was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"40112"}}